Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 8:17 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 30 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: ZD6474 (ZACTIMA) Clear all
Completed Phase 2 Interventional Results available

BATTLE Program: ZD6474 in Previously Treated Subjects With NSCLC

NCT00410189
View directory record Official record
Conditions
Lung Cancer
Interventions
ZD6474
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 22, 2015 · Synced Sep 23, 2026, 8:17 AM EDT
Completed Phase 1 Interventional Results available

Vandetanib and Everolimus in Treating Patients With Advanced or Metastatic Cancer

NCT01582191
View directory record Official record
Conditions
Advanced Malignant Neoplasm, Metastatic Malignant Neoplasm, Recurrent Malignant Neoplasm, Refractory Malignant Neoplasm
Interventions
Everolimus, Laboratory Biomarker Analysis, Pharmacological Study, Vandetanib
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 23, 2026, 8:17 AM EDT
Completed Phase 2 Interventional Results available

A Study To Assess ZD6474 (ZACTIMA™) Monotherapy In Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer

NCT00358956
View directory record Official record
Conditions
Thyroid Cancer
Interventions
ZD6474 (vandetanib)
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
2
States / cities
Little Rock, Arkansas • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 29, 2017 · Synced Sep 23, 2026, 8:17 AM EDT
Completed Phase 1 Interventional

Ph I Dose Escalation Trial of Vandetanib in Combo w Etoposide for Malignant Gliomas

NCT00613223
View directory record Official record
Conditions
Gliosarcoma, Glioblastoma
Interventions
Vandetanib and Etoposide
Drug
Lead sponsor
Annick Desjardins
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 19, 2013 · Synced Sep 23, 2026, 8:17 AM EDT
Completed Phase 2 Interventional Results available

Phase II Study of Vandetanib in Individuals With Kidney Cancer

NCT00566995
View directory record Official record
Conditions
Renal Cancer, Von Hippel Lindau
Interventions
ZACTIMA (Vandetanib) (ZD6474)
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 100 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 29, 2018 · Synced Sep 23, 2026, 8:17 AM EDT
Terminated Phase 1 Interventional

Radiation Therapy (XRT) and ZD6474 in Non-Small Cell Lung Cancer (NSCLC)

NCT00745732
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
ZD6474 (ZACTIMA), Radiation Therapy
Drug · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 13, 2018 · Synced Sep 23, 2026, 8:17 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Zactima With Temodar During Radiation Treatment for Newly Diagnosed Stage IV Brain Tumors

NCT00441142
View directory record Official record
Conditions
Glioblastoma Multiforme, Gliosarcoma
Interventions
ZD6474, temozolomide, Radiation Therapy
Drug · Radiation
Lead sponsor
Patrick Y. Wen, MD
Other
Eligibility
18 Years and older
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2017
U.S. locations
7
States / cities
Boston, Massachusetts • Detroit, Michigan • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2019 · Synced Sep 23, 2026, 8:17 AM EDT
Completed Phase 1 Interventional

Vandetanib and Radiation Therapy in Treating Young Patients With Newly Diagnosed Diffuse Brainstem Glioma

NCT00472017
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
vandetanib
Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
2 Years to 21 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 14, 2012 · Synced Sep 23, 2026, 8:17 AM EDT
Completed Phase 3 Interventional Results available

Efficacy Study Comparing ZD6474 in Combination With Pemetrexed and Pemetrexed Alone in 2nd Line NSCLC Patients

NCT00418886
View directory record Official record
Conditions
Non Small Cell Lung Cancer, Lung Cancer
Interventions
Vandetanib, Pemetrexed
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
698 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2023
U.S. locations
23
States / cities
Casa Grande, Arizona • Chandler, Arizona • Farmington, Connecticut + 20 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2024 · Synced Sep 23, 2026, 8:17 AM EDT
Completed Phase 1 Interventional

Ph I Zactima + Imatinib Mesylate & Hydroxyurea for Pts w Recurrent Malignant Glioma

NCT00613054
View directory record Official record
Conditions
Glioblastoma, Gliosarcoma
Interventions
Zactima, Gleevec, Hydroxyurea
Drug
Lead sponsor
Annick Desjardins
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 4, 2012 · Synced Sep 23, 2026, 8:17 AM EDT
Completed Phase 2 Interventional Results available

Randomized Study of Docetaxel +/- Vandetanib in Metastatic TCC

NCT00880334
View directory record Official record
Conditions
Transitional Cell Carcinoma, Bladder Cancer
Interventions
Docetaxel, vandetanib, Placebo
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 17, 2018 · Synced Sep 23, 2026, 8:17 AM EDT
Completed Phase 1 Interventional

Study of GemOx and Vandetanib in Advanced Solid Malignancy

NCT00660725
View directory record Official record
Conditions
Advanced Incurable Solid Malignancy
Interventions
Vandetanib, Gemcitabine, Oxaliplatin
Drug
Lead sponsor
Leonard Appleman
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 22, 2014 · Synced Sep 23, 2026, 8:17 AM EDT
Completed Phase 2 Interventional Results available

Docetaxel in Combination With Zactima (ZD6474) in Patients With Locally Advanced Squamous Cell Carcinoma of the the Head and Neck

NCT00459043
View directory record Official record
Conditions
Squamous Cell Carcinoma of Head and Neck
Interventions
ZD6474, Docetaxel
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
3
States / cities
Maywood, Illinois • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 2, 2013 · Synced Sep 23, 2026, 8:17 AM EDT
Completed Phase 2 Interventional Results available

A Phase II, Double Blind Study of 2 Doses of ZACTIMA™(ZD6474) in Combination With FOLFIRI vs FOLFIRI Alone for the Treatment of Colorectal Cancer in Patients

NCT00454116
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Vandetanib, FOLFIRI
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
4
States / cities
Ann Arbor, Michigan • New York, New York • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2016 · Synced Sep 23, 2026, 8:17 AM EDT
Terminated Phase 2 Interventional Results available

Vandetanib, Carboplatin, and Paclitaxel in Treating Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer That Can Be Removed by Surgery

NCT00459121
View directory record Official record
Conditions
Lung Cancer
Interventions
carboplatin, paclitaxel, Zactima, neoadjuvant therapy
Drug · Procedure
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years to 120 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 25, 2019 · Synced Sep 23, 2026, 8:17 AM EDT
Completed Phase 1 Interventional

Open Label, Phase I ZD6474 Head and Neck Cancer Study

NCT00450138
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
ZD6474 (vandetanib), Cisplatin, Radiation
Drug · Radiation
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
4
States / cities
Denver, Colorado • Chicago, Illinois • Dallas, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2016 · Synced Sep 23, 2026, 8:17 AM EDT
Completed Phase 1 Interventional

Dose Escalation Study of Vandetanib With Hypofractionated Stereotactic Radiotherapy in Recurrent Malignant Gliomas

NCT00822887
View directory record Official record
Conditions
Malignant Gliomas
Interventions
Vandetanib, Fractionated Stereotactic Radiotherapy
Drug · Radiation
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 25, 2013 · Synced Sep 23, 2026, 8:17 AM EDT
Terminated Phase 1 Interventional

ZD6474 Alone and in Combination With Retinoic Acid in Pediatric Neuroblastoma

NCT00533169
View directory record Official record
Conditions
Neuroblastoma
Interventions
ZD6474, Retinoic Acid
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
2 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 14, 2011 · Synced Sep 23, 2026, 8:17 AM EDT
Terminated Phase 2 Interventional Results available

Phase 2 Anastrozole and Vandetanib (ZD6474) in Neoadjuvant Treatment of Postmenopausal Hormone Receptor-Positive Breast Cancer

NCT00481845
View directory record Official record
Conditions
Breast Cancer
Interventions
Vandetanib, Anastrozole
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older · Female only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Feb 6, 2017 · Synced Sep 23, 2026, 8:17 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Vandetanib to Treat Children and Adolescents With Medullary Thyroid Cancer

NCT00514046
View directory record Official record
Conditions
Medullary Thyroid Carcinoma, Multiple Endocrine Neoplasia Type 2A, Multiple Endocrine Neoplasia Type 2B
Interventions
Vandetanib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
5 Years to 18 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 21, 2020 · Synced Sep 23, 2026, 8:17 AM EDT
Terminated Phase 2 Interventional Results available

Phase II Study of ZD6474 in Advanced NSCLC

NCT00290537
View directory record Official record
Conditions
Lung Cancer
Interventions
ZD6474, Carboplatin, Paclitaxel
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 18, 2016 · Synced Sep 23, 2026, 8:17 AM EDT
Completed Phase 3 Interventional Results available

ZACTIMA (an Anti-EGFR / Anti-VEGF Agent) Combined With Docetaxel Compared to Docetaxel in Non-small Cell Lung Cancer

NCT00312377
View directory record Official record
Conditions
Non-small Cell Lung Cancer, Lung Cancer
Interventions
Docetaxel, Vandetanib
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
1,690 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
27
States / cities
Fullerton, California • Los Angeles, California • Northridge, California + 24 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2016 · Synced Sep 23, 2026, 8:17 AM EDT
Completed Phase 3 Interventional Results available

ZD6474 (ZACTIMA™) Phase III Study in EGFR Failures

NCT00404924
View directory record Official record
Conditions
Non-Small-Cell Lung Carcinoma
Interventions
ZD6474 (vandetanib), Best Supportive Care
Drug · Other
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
1,140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
2
States / cities
Tucson, Arizona • Germantown, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 29, 2016 · Synced Sep 23, 2026, 8:17 AM EDT
Completed Phase 3 Interventional Results available

Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy

NCT00364351
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Vandetanib, Erlotinib
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
1,574 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2016
U.S. locations
29
States / cities
Berkeley, California • Los Angeles, California • Santa Rosa, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2018 · Synced Sep 23, 2026, 8:17 AM EDT